Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants

Journal of Affective Disorders

Volumn 173, Issue , 2015, Pages 211-215

  Popovic, Dina ^a   Vieta, Eduard ^a   Fornaro, Michele ^b   Perugi, Giulio ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Antidepressant; Cognitive side effects; Long term; SSRI; Tolerability

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGORAPHOBIA; ANXIETY DISORDER; APATHY; ARTICLE; ATTENTION DISTURBANCE; BULIMIA; COGNITION; COGNITIVE DEFECT; CONCENTRATION LOSS; DISEASE SEVERITY; DRUG TOLERABILITY; EMOTIONAL DISORDER; FATIGUE; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEMORY DISORDER; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; PANIC; SOCIAL INTERACTION; SOCIAL PHOBIA; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; WELLBEING; ANXIETY DISORDERS; CHEMICALLY INDUCED; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; APATHY; COGNITION; DEPRESSIVE DISORDER, MAJOR; FATIGUE; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 84912101673     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2014.11.008     Document Type: Article

References (18)

1. C. De las Cuevas, and E.J. Sanz Safety of selective serotonin reuptake inhibitors in pregnancy Curr. Drug Saf. 1 1 2006 17 24
2. G.I. Papakostas, J.C. Nelson, and S. Kasper A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Eur. Neuropsychopharm. 18 2 2008 122 127
3. D. Brent, G. Emslie, and G. Clarke Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial JAMA 299 8 2008 901 913
4. S.M. McClintock, M.M. Husain, S.R. Wisniewski, A.A. Nierenberg, J.W. Stewart, M.H. Trivedi, I. Cook, D. Morris, D. Warden, and A.J. Rush Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication J. Clin. Psychopharm. 31 2 2011 180 186
5. D.S. Baldwin The importance of long-term tolerability in achieving recovery Int. J. Psychiat. Clin. Prac 10 Suppl 1 2006 31 37
6. G.I. Papakostas Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice J. Clin. Psychiat. 75 1 2014 8 14
7. E. Vieta The bipolar maze: a roadmap through translational psychopathology Acta Psychiat. Scand. 129 5 2014 323 327
8. E. Vieta, D. Popovic, and A.R. Rosa The clinical implications of cognitive impairment and allostatic load in bipolar disorder Eur. Psychiat. 28 2013 21 29
9. R.S.E. Keefe, S.M. McClintock, R.M. Roth, P.M. Doraiswamy, S. Tiger, and M. Madhoo Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review J. Clin. Psych.Psych. 75 8 2014 864 876
10. R.S. McIntyre, S. Lophaven, and C.K. Olsen A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults Int. J. Neuropsychopharm. 30 2014 1 11
11. P. Cassano, and M. Fava Tolerability issues during long-term treatment with antidepressants Ann. Clin. Psychiat 16 1 2004 15 25
12. L. Baer, D.G. Jacobs, and J. Meszler-Reizes Development of a brief screening instrument: the hands Psychother. Psyc. 69 1 2000 35 41
13. R.J. Baldessarini Chemotherapy in Psychiatry. Pharmacologic Basis of Treatments for Major Mental Illness third ed 2013 Springer, 183
14. M.Y. Bolling, and R.J. Kohlenberg Reasons for quitting serotonin reuptake inhibitor therapy: paradoxical psychological side effects and patient satisfaction Psychother Psyc. 73 2004 380 385
15. X.H. Hu, S.A. Bull, and E.M. Hunkeler Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate J. Clin. Psychiat. 65 2004 959 965
16. M. Fava, L.M. Graves, and F. Benazzi A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment J. Clin. Psychiatr. 67 11 2006 1754 1759
17. K. Kelly, M. Posternak, and J.E. Alpert Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin. Neurosci. 10 4 2008 409 418
18. A. Serretti, R. Calati, A. Goracci, M. Di Simplicio, P. Castrogiovanni, and D. De Ronchi Antidepressants in healthy subjects: what are the psychotropic/psychological effects? Eur Neuropsychopharm 20 7 2010 433 453